FMP
Cellectar Biosciences, Inc.
CLRB
NASDAQ
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
0.271 USD
0.0065 (2.4%)
2024
2023
2022
2021
24.25M
10.45M
20.53M
36.57M
23.29M
9.56M
19.87M
35.7M
23.29M
9.56M
19.87M
35.7M
0
0
0
0
0
0
0
0
0
0
0
0
961.66k
888.23k
663.24k
867.49k
1.22M
1.62M
1.06M
630.35k
1.19M
1.59M
978.98k
549.13k
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29.78k
29.78k
81.21k
81.21k
0
0
0
0
25.47M
12.08M
21.59M
37.2M
-
-
-
-
9.39M
25.36M
5.53M
3.99M
611k
5.62M
2.56M
1.42M
84.42k
0
50.85k
135.45k
0
0
0
0
0
0
0
2.44M
8.69M
18.19M
1.95M
368.46k
9.39M
25.36M
5.53M
3.99M
1.79M
494k
552.98k
166.29k
0
0
0
0
0
0
0
0
0
0
0
0
1.79M
0
0
0
11.18M
25.85M
6.08M
4.16M
0
0
0
0
14.29M
-15.16M
15.51M
33.05M
461
207
94
611
-247.34M
-217.48M
-179.5M
-150.9M
0
0
0
0
261.12M
13.34M
0
0
25.47M
12.08M
21.59M
37.2M
2024
2023
2022
2021
-217.48M
-179.5M
-150.9M
-126.78M
-44.58M
-37.98M
-28.6M
-23.97M
0
0
0
0
0
0
0
0
-247.34M
-217.48M
-179.5M
-150.9M
-29.86M
-37.98M
-28.6M
-24.12M
2024
2023
2022
2021
1.19M
1.59M
978.98k
549.13k
0
192.38k
238.87k
227.64k
-104.19k
-864.04k
-225.97k
-141.36k
1.3M
2.26M
966.08k
462.86k
2024
2023
2022
2021
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.